# breast cancer - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 30530
- Completion tokens: 6271
- Reasoning tokens: 2849
- Total tokens: 36801
- API requests reported: 2
- Elapsed seconds: 108.137
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: xAI

---
**Overall biological interpretation**  
The prognostic signature for overall survival in breast tumor tissue is strongly biased toward cell-cycle machinery, with 52 risk-associated genes (HR > 1) clustered in mitotic progression and spindle dynamics, contrasted by 48 protective genes (HR < 1) enriched for immune signaling, collagen/extracellular-matrix components, and transcriptional regulators. This indicates that accelerated mitotic activity in tumor cells drives poorer outcome, while immune-cell infiltration and stromal-matrix preservation confer benefit. STRING interactions within the risk set further reinforce a cohesive mitotic module (e.g., PLK1–AURKA–CDC20–TPX2–PRC1 network), while protective genes map to extracellular-region and plasma-membrane compartments.

**Core biological programs**  

**Program 1: Mitotic cell-cycle progression (risk-associated)**  
Direction: Risk (HR > 1)  
Major genes: AURKA, CDC20, CDCA5, CENPO, KIF20A, KIF4A, NUSAP1, PRC1, TPX2, UBE2C, ZWINT, UHRF1, TK1, CCNE2, PSMD3  
Pathway: KEGG Cell cycle; GO Positive Regulation of Mitotic Nuclear Division (GO:0045840)  
Supporting genes indicate this program because they encode core mitotic regulators (spindle assembly, APC/C activators, kinase complexes, checkpoint proteins) whose coordinated upregulation increases proliferation rate and is directly linked to worse OS. STRING edges (e.g., AURKA–CDC20–KIF20A–PKMYT1, TPX2–PRC1–NUSAP1) show pathway co-membership and co-expression.  
Evidence strength: Direct dataset (100 genes with FDR < 1e-6), GO/KEGG annotations, STRING network; genuinely independent across multiple mitotic sub-modules.  
Limitations: HRs reflect correlation with proliferation, not necessarily causation; tumor-purity or immune infiltration may confound.

**Program 2: Extracellular-matrix remodeling and collagen organization (protective)**  
Direction: Protective (HR < 1)  
Major genes: COL17A1, LAMA2, COL14A1, MFAP4, IGSF10, RELN  
Pathway: GO Extracellular matrix organization; Reactome Collagen formation  
These genes collectively point to a program because they encode structural-collagen components and associated matrix proteins whose higher expression associates with improved survival, consistent with a more differentiated or less invasive stromal phenotype. Tissue-specific evidence (GTEx/HPA) shows breast-tumor enrichment.  
Evidence strength: Direct dataset, pathway co-membership, tissue-expression records; partially overlapping with literature on ECM in breast-cancer prognosis.  
Limitations: May capture stromal composition rather than tumor-intrinsic effects; no independent-cohort HRs supplied.

**Program 3: JAK–STAT and immune signaling (protective)**  
Direction: Protective (HR < 1)  
Major genes: STAT5A, STAT5B, JCHAIN, FCER1A, IL27RA  
Pathway: GO Immune response; KEGG Cytokine–cytokine receptor interaction  
STAT-family and immunoglobulin-related genes indicate an immune-modulatory program whose activation associates with better OS, aligning with immune-cell infiltration signals reported in the literature. STRING shows regulatory interactions among STAT5A/B and JCHAIN.  
Evidence strength: Direct dataset, pathway annotations, literature-supported immune infiltration; sources overlap (e.g., same PubMed articles).  
Limitations: STAT5A/B HRs are modest; no independent cohort statistics; immune-cell deconvolution not performed.

**Program 4: Serine/threonine kinase and metabolic signaling (mixed)**  
Direction: Mixed (GSK3B risk, CPT1A risk)  
Major genes: GSK3B, ATP2A2, CPT1A, AK3  
Pathway: KEGG Cell-cycle + ErbB signaling; GO Serine/threonine kinase activity  
These kinases point to a broader signaling module modulating cell survival and metabolism; GSK3B and ATP2A2 (risk) contrast with CPT1A (risk but lower HR). STRING confirms GSK3B–AXIN1–CTNNB1 interactions.  
Evidence strength: Direct dataset, STRING and QuickGO records; partially redundant with Program 1.  
Limitations: Single-gene elevation does not establish causality; no independent validation statistics.

**Key genes and interaction modules** (selected for network centrality)  
- LARP1 (risk, HR 1.26): ribosomal RNA-binding protein; STRING links to NUSAP1/TPX2 in mitotic module; co-expression with cell-cycle genes.  
- PKMYT1 (risk, HR 1.24): Wee1-family kinase; STRING edge to AURKA; regulatory interaction with mitotic checkpoint.  
- STAT5A (protective, HR 0.81): transcription factor; STRING regulatory links to FLT3/LEPR; pathway co-membership in JAK–STAT.  
- COL17A1 (protective, HR 0.80): collagen XVII; extracellular-region compartment; no direct physical interaction data.  
- AURKA (risk, HR 1.19): mitotic kinase; STRING hub with CDC20, TPX2, BUB1B; direct physical + co-expression with PLK1.  
- CDC20 (risk, HR 1.19): APC/C activator; STRING edges to UBE2C/UBE2S; pathway co-membership in mitotic exit.  
- TPX2 (risk, HR 1.20): spindle-assembly factor; STRING edges to AURKA/KIF4A/PRC1; direct physical interaction with AURKA.  
- PRC1 (risk, HR 1.19): cytokinesis regulator; STRING edges to TPX2/NUSAP1; co-expression within mitotic module.  
- GSK3B (risk, HR 1.23): Wnt/beta-catenin kinase; STRING interactions with AXIN1/CTNNB1; regulatory interaction with APC.  
- JCHAIN (protective, HR 0.80): IgA polymerization factor; immune-cell signature; regulatory interaction with STAT5A.

**Validation priorities**  
1. **Biomarker**: COL17A1 and STAT5A (protective) – Current dataset provides direct HRs; external literature links them to immune infiltration and prognosis; next step: validation in independent TCGA or METABRIC cohort; exploratory hypothesis.  
2. **Mechanistic hypothesis**: AURKA/TPX2 mitotic module – Dataset shows coordinated risk HRs and STRING edges; external evidence supports role in breast-cancer proliferation; next step: siRNA or CRISPR perturbation in breast-cancer cell lines followed by proliferation assays; supported hypothesis.  
3. **Interaction/network hypothesis**: STRING mitotic sub-network (AURKA–CDC20–TPX2) – Dataset + STRING provide co-membership; no independent physical-interaction assays; next step: co-IP or proximity ligation in breast-cancer models; exploratory hypothesis.  
4. **Confounding or composition check**: Immune-cell fraction – Dataset lacks deconvolution; external GTEx/HPA show tissue specificity; next step: CIBERSORT or MCP-counter on same microarray; exploratory hypothesis.  
5. **Therapeutic target**: GSK3B (risk) – Dataset HR 1.23; literature shows GSK3B inhibitors in breast cancer; next step: screen approved GSK3 inhibitors in GSK3B-high patient-derived xenografts; supported hypothesis (drug evidence noted but not causal).

**Evidence grounding**  
- Direct evidence from input dataset: all HR, P, FDR values (100 genes).  
- Pathway/ontology: KEGG Cell cycle, GO mitotic-division, extracellular-matrix terms (QuickGO/Reactome).  
- Protein interaction: STRING edges (50 within selected set) – regulatory and co-expression, not always direct physical.  
- Disease-association: multiple PubMed/Europe PMC hits for COL17A1, STIP1, PPIL3, AURKA (overlapping sources).  
- Expression/tissue-specific: GTEx/HPA/Ensembl records.  
- No independent-cohort statistics supplied; external validation status = not_available. No conflicting evidence; all sources consistent with dataset direction.

**Limitations and alternative explanations**  
- Tumor-purity and immune-cell composition differences can inflate mitotic-gene signals (investigable by CIBERSORT deconvolution).  
- Batch/platform effects possible in microarray platform (no correction details supplied).  
- Small-subgroup effects (e.g., ER+ vs ER–) not stratified.  
- Association-versus-causation ambiguity: HRs reflect correlation, not proven driver status.  
- Overlap between programs (e.g., mitotic genes also appear in ErbB signaling) reduces specificity.  
- No external replication statistics provided; conclusions remain exploratory.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=11, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
